Evidence map›Paper›PMID 42509645›Full record

ArticleCancer medicine2026

ATF4, ZIK1, and PNMA3 Transcriptomic Signatures Predict Chemoradiotherapy Response in Cervical Cancer.

Angelo Borges de Melo Neto, Fábio Ribeiro Queiroz, Carolina Pereira de Souza Melo, Bruna Custódio Dias Duarte, Jorge Gomes Goulart Ferreira, Izabela Ferreira Gontijo de Amorim, Laurence Rodrigues do Amaral, Pedro Luiz Lima Bertarini, Telma Maria Rossi de Figueiredo Franco, Andréa Teixeira de Carvalho and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Angelo Borges de Melo NetoLaboratório de Bioinformática e Análises Moleculares, Universidade Federal de Uberlândia, Patos de Minas, Brazil.
Fábio Ribeiro QueirozLaboratório de Pesquisa Básica e Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte, Brazil.
Carolina Pereira de Souza MeloLaboratório de Pesquisa Básica e Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte, Brazil.
Bruna Custódio Dias DuarteLaboratório de Bioinformática e Análises Moleculares, Universidade Federal de Uberlândia, Patos de Minas, Brazil.ORCID https://orcid.org/0000-0002-6628-7185
Jorge Gomes Goulart FerreiraLaboratório de Pesquisa Básica e Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte, Brazil.
Izabela Ferreira Gontijo de AmorimLaboratório de Pesquisa Básica e Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte, Brazil.
Laurence Rodrigues do AmaralLaboratório de Bioinformática e Análises Moleculares, Universidade Federal de Uberlândia, Patos de Minas, Brazil.
Pedro Luiz Lima BertariniLaboratório de Bioinformática e Análises Moleculares, Universidade Federal de Uberlândia, Patos de Minas, Brazil.
Telma Maria Rossi de Figueiredo FrancoLaboratório de Pesquisa Básica e Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte, Brazil.
Andréa Teixeira de CarvalhoGrupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Belo Horizonte, Brazil.ORCID https://orcid.org/0000-0003-2814-5183
Olindo Assis Martins-FilhoGrupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Belo Horizonte, Brazil.
Wander de Jesus JeremiasLaboratório de Farmacologia Experimental, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.
Letícia da Conceição BragaLaboratório de Pesquisa Básica e Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte, Brazil.ORCID https://orcid.org/0000-0002-6181-9410
Paulo Guilherme de Oliveira SallesLaboratório de Pesquisa Básica e Translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna, Belo Horizonte, Brazil.
Matheus de Souza GomesLaboratório de Bioinformática e Análises Moleculares, Universidade Federal de Uberlândia, Patos de Minas, Brazil.

Funding

Brazilian Ministry of Health NUP:25000.079266/2015-09Brazilian Ministry of Health NUP:25000.159953/2014-18Conselho Nacional de Desenvolvimento Científico e TecnológicoFundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG APQ-02255-22Rede Mineira de Pesquisa Translacional em Oncologia RED00059-23
6 · The paper itself

Abstract

backgroundCervical cancer (CC) is a main malignancy affecting women globally, with a high mortality rate. Chemoradiotherapy resistance is a significant factor in determining treatment outcomes, and prognostic biomarkers are essential for the appropriate selection of therapeutic strategies. This study aimed to identify gene expression signatures that may allow for follow-up treatment response in CC patients.

methodsSamples of non-stem CC cells selected by Fluorescence-activated Cell Sorting from 21 Responders and 10 Non-responder patients, who attended the Mario Penna Institute (Belo Horizonte-Brazil) from August 2017 to May 2018, and submitted to Next-generation RNA sequencing, were analyzed to evaluate differential gene expression profiles between both groups. Machine Learning and statistical analyses were performed to identify a signature related to clinical outcomes.

results2670 Differentially expressed genes (DEGs) with log

conclusionsWe propose that upregulation of PNMA3 and downregulation of ATF4, specifically in cervical cancer non-stem cells, is associated with upregulation of ZIK1 and with resistance to apoptosis and chemoradiotherapy. Therefore, suggesting that these genes may serve as potential signatures for CC prognosis.

Indexed as

Activating Transcription Factor 4ChemoradiotherapyTranscriptomeUterine Cervical NeoplasmsBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisActivating Transcription Factor 4ATF4 protein, humanBiomarkers, TumorATF4cervical cancerchemoradiotherapy resistancePNMA3ZIK1

Identifiers

PMID42509645
PMCPMC13408019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.